Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Jan 9, 2026--

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109621764/en/

The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.

“This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Based on the preclinical research conducted to date, we believe that the combination of Biocytogen’s RenLite ® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific ADCs.”

“This option-based framework allows us to systematically assess how dual-payload conjugation strategies can be applied to bispecific antibody formats,” said Sonny Hsiao, Ph.D., Chairman and CEO of Acepodia. “This collaboration reflects our focus on disciplined, data-driven AD2C platform expansion.”

The expanded partnership is intended to leverage complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia’s internal governance and option exercise criteria.

About Biocytogen

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

Biocytogen has independently developed its proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® /RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

About Acepodia

Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. Acepodia’s conjugation platforms are designed for modular integration across antibodies, immune cells, and payload architectures, enabling flexible application across diverse therapeutic modalities. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

WASHINGTON (AP) — Defense Secretary Pete Hegseth said Thursday that he will allow service members to carry personal weapons onto military installations, citing the Second Amendment and recent shootings at bases across the country.

In a video posted to X, Hegseth said he is signing a memo that will direct base commanders to allow requests for troops to carry privately owned firearms “with the presumption that it is necessary for personal protection.”

He said any denial of a service member's request must be explained in detail and in writing.

“Effectively, our bases across the country were gun-free zones,” Hegseth said. “Unless you're training or unless you are a military policeman, you couldn't carry, you couldn't bring your own firearm for your own personal protection onto post.”

Questions about why service members lacked access to weapons have often emerged following shootings on the nation's military bases. Such shootings have ranged from isolated events between service members to mass casualty events, such as the shootings by an Army psychiatrist at Texas’ Ford Hood in 2009 that left 13 people dead.

Hegseth cited some of the events in his video, including a shooting that injured five soldiers at Fort Stewart in Georgia last year. Officials said the shooter, an Army sergeant who worked at the base, used his personal handgun before he was tackled by fellow soldiers and arrested.

“In these instances, minutes are a lifetime,” Hegseth said. “And our service members have the courage and training to make those precious, short minutes count.”

Defense Department policy has prohibited military personnel from carrying personal weapons on base without permission from a senior commander, with strict protocol for how the firearms must be stored.

Typically, military personnel must officially check their guns out of secure storage to go to on-base hunting areas or shooting ranges, then check all firearms back in promptly after their sanctioned use. Military police are often the only armed personnel on base, outside of shooting ranges, hunting areas or in training, where soldiers can wield their service weapons without ammunition.

Tanya Schardt, senior counsel at the Brady gun violence prevention organization, said in a statement that Defense Department leaders and the military’s top brass have opposed relaxing the current policy, which was originally enacted under President George H.W. Bush.

Schardt noted that most active duty service members who die by suicide do so with a weapon they own personally, not one military-issued, and argued that there will “undoubtedly be an increase in gun suicide and other gun violence.”

While fewer American service members died by suicide in 2024, the suicide rates among active duty troops overall still have gradually increased between 2011 and 2024, according to a Pentagon report released Tuesday.

“Our military installations are among the most guarded, protected properties in the world, and they’ve never been ‘gun-free zones,’” Schardt said. “If there is a problem with violent crime on these installations, then the Secretary of Defense has an obligation to alert the American people and describe how he’s working to prevent that crime.”

Defense Secretary Pete Hegseth speaks to members of the media during a press briefing at the Pentagon in Washington, Tuesday, March 31, 2026. (AP Photo/Manuel Balce Ceneta)